Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

TetraLogic Ends Birinapant MDS Trial After No Clinical Benefit Seen Over Placebo

This article was originally published in Scrip

Executive Summary

TetraLogic Pharmaceuticals Corp has ended a placebo controlled Phase II study of birinapant co-administered with azacitidine in first line patients suffering from the blood disorder myelodysplastic syndromes (MDS) after the SMAC-mimetic failed to show any clinical benefit over placebo.

You may also be interested in...



Medivir's Oncology Asset Purchase Seals TetraLogic's Death

Medivir, which recently reinvented itself as a solely oncology-based R&D company, is buying two programs for TetraLogic which will subsequently 'terminate all remaining employees'.

Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies

Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.   

Incyte Plays Down Ruxolitinib Cream Label Worries Following Atopic Dermatitis Approval

Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.

Topics

UsernamePublicRestriction

Register

SC064148

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel